Trial Profile
A 56-Week Extension to a Clinical Study to Assess the Efficacy and Safety of Vildagliptin Compared to Placebo in Drug Naive Patients With Type 2 Diabetes and Mild Hyperglycemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Aug 2017
Price :
$35
*
At a glance
- Drugs Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novartis
- 04 Aug 2017 New trial record